Takeda Reports the MHLW’s Approval of Fruzaqla (Fruquintinib) to Treat Unresectable Advanced or Recurrent Colorectal Cancer (CRC)
Shots:
- The MHLW has approved Fruzaqla (oral, 1mg/5mg), a VEGFR-1, 2 & 3 inhibitor, to treat inoperable, advanced or recurrent CRC. Takeda is exclusively responsible for the development, commercialization & manufacturing of the drug outside of mainland China, Hong Kong & Macau
- Approval was based on P-III (FRESCO-2) study assessing the safety & efficacy of Fruzaqla + best supportive care (BSC) vs PBO + BSC in treatment-experienced mCRC patients across the US, EU, Japan & Australia
- Study reached all the 1 & 2EPs, showing consistent benefits in patients, irrespective of previous treatment. Safety profile was favorable with 20% vs 21% discontinuation due to AEs. Data was published in The Lancet in Jun 2023
Ref: Takeda | Image: Takeda
Related News:- Takeda’s Fruzaqla Gains the EC’s Approval for the treatment of Metastatic Colorectal Cancer
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
